The allowed patent claims address an essential element in the company’s proprietary technology that automatically controls nerve stimulation to optimize pain relief. In particular, the patent covers a novel calibration procedure that customizes nerve stimulation for each Quell user.
In addition, the allowed patent claims protect the unique integrated Quell design that combines a neurostimulator, an electrode array, and an accelerometer. This technology enables automatic adjustment of nerve stimulation based on the user’s position and movement, with applications such as optimizing therapy during sleep. The company expects the three patents to formally issue by the third quarter of 2017.
“We are pleased to have received these important Notice of Allowances for the Quell technology in the European Union, Japan and China. These are the three key expansion markets for the Quell business,” said Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix. "We are currently in discussions with strategic partners about licensing or distributing Quell outside our core North American market. These patent claim allowances may help advance these discussions towards formal agreements.”
Quell is designed for people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the U.S. Food and Drug Administration for treatment of chronic pain without a prescription. In a recent study, 81 percent of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait.
NeuroMetrix is a commercial stage healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Mass., and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996.